MK-677 for Muscle Growth (Research-Reported)

What does MK-677 do for muscle growth, according to the trial?

In the one large randomized trial, MK-677 raised fat-free mass by about 1.1 kg over 12 months, but that lean tissue did not come with a matching strength gain (Nass et al., 2008).

MK-677, also called ibutamoren, is an orally active ghrelin-mimetic growth hormone secretagogue. It binds the same receptor ghrelin uses and prompts the pituitary to release more of the body's own growth hormone, which in turn raises IGF-1. This is different from injecting growth hormone directly.

The key human data point is Nass et al., 2008, published in Annals of Internal Medicine. Older adults received 25 mg per day of oral MK-677 or placebo for one year. The MK-677 group gained about 1.1 kg of fat-free mass compared with placebo. On paper, that is a real body-composition signal from an oral compound.

The honest limit: more lean mass did not equal more useful output. The trial did not show that the added fat-free mass produced better strength or better physical function. So "muscle growth" in the scale-weight sense and "stronger, more functional muscle" are not the same claim, and the published evidence only supports the first one, weakly.

Is the fat-free mass gain worth the glucose tradeoff?

That is the question the trial forces, because the same 25 mg/day dose that raised lean mass also raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008).

This is the finding most generic write-ups skip. In Nass et al., 2008, MK-677 did not just nudge body composition. It also moved metabolic markers in the wrong direction: fasting blood glucose went up and insulin sensitivity went down over the study period. For a compound taken specifically to add tissue, a shift toward worse glucose handling is a meaningful counterweight, not a footnote.

Growth hormone secretagogues raise GH and IGF-1, and raised GH signaling is known to blunt insulin action. So the glucose effect is consistent with the mechanism, not a random result. Anyone weighing this compound has to weigh a small lean-mass number against a measurable metabolic cost, and that math is individual. It belongs to a clinician who can see your labs.

How does MK-677 compare with injectable GH secretagogues?

MK-677 is oral and long-acting on GH release, while peptides like CJC-1295 and ipamorelin are injectable and act through the GHRH or ghrelin pathways with their own profiles.

Note what the table does and does not say. It reports what each study measured. None of these entries is a body-composition promise to you, and only MK-677 carries the specific fat-free-mass-versus-glucose finding from a 12-month randomized design.

What dose did the research use?

In the trial, participants received 25 mg per day of oral MK-677; this is a research-reported figure, not a recommendation.

This table describes what one trial administered and observed. It is not guidance on what to take, when, or for how long. Your personal dose, if any, is a clinical decision. Route that to a qualified clinician who can factor in your glucose status and full history.

Why does lean mass not equal strength here?

Because in the trial the added fat-free mass did not carry a matching improvement in strength or function, which means scale-level lean gain and real-world capacity are separate outcomes (Nass et al., 2008).

Fat-free mass on a body-composition scan includes water and non-contractile tissue, not just working muscle fiber that produces force. A GH and IGF-1 rise can increase fluid retention and lean-tissue mass without proportionally increasing the strength that muscle can generate. That is one reason a lean-mass number can move while functional tests stay flat. The trial's own results reflect this gap, so it is fair to describe MK-677 as changing a body-composition marker rather than reliably building performance.